Larimar Therapeutics, Inc. (LRMR)

Larimar Therapeutics' stock price has experienced significant fluctuations in the past six months. Key events impacting the stock include earnings reports, adverse events in a clinical trial, positive clinical data and program updates, a public offering, and analyst ratings and price target adjustments. The company reported a Q3 2025 earnings per share (EPS) of -$0.61, missing the consensus estimate of -$0.42. In December 2024, the stock experienced a significant decline following reports of serious adverse events (SAEs) affecting two patients in its Friedreich's ataxia treatment study. In September 2025, Larimar Therapeutics announced positive data from its ongoing long-term open-label study of nomlabofusp. In July 2025, Larimar Therapeutics announced the closing of an underwritten public offering of common stock. Analysts have provided a consensus recommendation of "Moderate Buy" for LRMR, with an average 12-month target price of $16.71.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company and does not generate commercial product revenue as of November 2025. The company's financial model is currently driven by capital raises and interest income, funding its research and development efforts. Traditional demand seasonality is not applicable to Larimar Therapeutics, as its revenue generation is contingent on obtaining regulatory approvals for its therapies.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, operating within the Healthcare sector, specifically in the Biotechnology and Medical Research industry. The company utilizes a novel cell penetrating peptide (CPP) technology platform, with its lead product candidate, nomlabofusp, currently in a Phase 2 OLE clinical trial for Friedreich's ataxia (FA).

Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania, United States, and plans to expand its presence in international markets by seeking regulatory approvals and establishing partnerships with global organizations. A global Phase 3 study is being prepared with sites identified and qualified in the U.S., Europe, U.K., Canada, and Australia.

Larimar Therapeutics' reputation has been shaped by both positive clinical advancements and challenges. Positive data from its ongoing long-term open-label study of nomlabofusp and FDA recommendations have supported the company's reputation. However, the company's reputation was impacted in December 2024 when its stock fell significantly due to reports of serious adverse events in its clinical study, and ongoing investigations by law firms regarding potential securities claims can also affect brand perception.

Larimar Therapeutics, Inc. is primarily owned by institutional shareholders, who hold 99.91% of the stock, while insiders own 74.91% and retail investors hold 0.00%. Major institutional owners include Deerfield Management Company, L.P., RA Capital Management, L.P., and BlackRock, Inc. The largest individual shareholder is James E. Flynn, owning 38.16 million shares, which represents 44.59% of the company.